Mayo Clinic | Strategic Alliance Partners

In recognition of Rare Disease Day, the NeurologyLive® team offered an extensive update on the state of care and treatment for a few rare neurological diseases, including Pompe disease, Rett syndrome, among others.

The director of the Alzheimer’s Disease Research Center at Mayo Clinic detailed the current issues with access and affordability to critical biomarkers in the screening and monitoring of patients in Alzheimer disease trials. [WATCH TIME: 3 minutes]

The director of the Alzheimer’s Disease Research Center at Mayo Clinic provided insight on new considerations for interpreting data from cognitive and functional measures in trials assessing agents for Alzheimer disease.

The director of the Alzheimer’s Disease Research Center at Mayo Clinic provided perspective on the emergence in antiamyloid therapies, assessing clinically meaningful benefit, and potential changes to trial design in the future. [WATCH TIME: 3 minutes]

The director of the Alzheimer’s Disease Research Center at Mayo Clinic discussed a recently published paper focused on the expectations and clinical meaningfulness of randomized controlled trials in Alzheimer disease. [WATCH TIME: 4 minutes]

After 12 weeks of treatment, almost twice as many patients on eptinezumab reported either “much improved” or “very much improved” than those on placebo, according to Patient Global Impression of Change.

Patients who had higher baseline REM without atonia levels were associated with the largest treatment effects on RSWA with a single 50 mg dose of ulotaront.

An updated literature review provided data to assist with the revisioning of quality measures in in clinical practice for adults with obstructive sleep apnea.

Over a median of 73.5 weeks of follow-up time, zero adjudicated relapses were observed for those with AQP4+ NMOSD on ravulizumab.

Experts such as Brenda Banwell, MD; Sean Pittock, MD; and Michael Levy, MD, PhD, cover topics related to differences in rare neuroimmune disorders, how they're approached and treated.

The chair of the nephrology division at Mayo Clinic provided context on recent findings linking inflammation and neurovascular damage in women with a history of severe preeclampsia, and how the community may react. [WATCH TIME: 2 minutes]

Vesna Garovic, MD, PhD, chair of the nephrology division at Mayo Clinic, discussed the appropriate reaction to data suggesting late-life elevated inflammation and neurovascular damage from severe preeclampsia.

The chair of the nephrology division at Mayo Clinic discussed the major questions surrounding preeclampsia and its long-term effects, as well as whether new findings change the way clinicians treat patients with the condition. [WATCH TIME: 4 minutes]

The chair of the nephrology division at Mayo Clinic provided context on new findings on the risks of preeclampsia, a hypertensive disorder, and elevated levels of neuroinflammation and neurovascular damage.

The nephrologist at Mayo Clinic provided insight on new data showing elevated extracellular vesicles of neurovascular origin in women with a history of severe preeclampsia years after pregnancy. [WATCH TIME: 4 minutes]

Inflammatory coagulation pathway activator positive extracellular vesicles were significantly increased in women with a history of severe preeclampsia compared with controls and those with milder cases.

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the technological capabilities the center has, including the improved use of neural antibody testing. [WATCH TIME: 6 minutes]

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided insight on a unique way the institution cares for patients who present with an inflammatory or autoimmune entity. [WATCH TIME: 5 minutes]

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the complexities in diagnosing autoimmune encephalitis and the approach needed to be taken. [WATCH TIME: 5 minutes]

Through dedicated research into biomarker discovery and patient care, the neuroimmunology laboratory at Mayo Clinic has paved a new way of life for those with autoimmune disorders.

In the open-label extension where the highest dose of atogepant (Qulipta; AbbVie) was observed, 24.1% of participants had at least 7% weight loss compared with 14.7% of those on standard of care.

The journey of aducanumab (Aduhelm; Biogen) from development to the FDA is a tortured one, but its path may serve to teach the Alzheimer disease field valuable lessons as it strives forward to develop disease-modifying therapies.

Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.

The associate professor of neurology at Mayo Clinic and member of the board of directors at AHS shared her perspective on the importance of collecting more information on status migrainosus and the need to develop a better approach and definition. [WATCH TIME: 3 minutes]

Only 17% of patients who received 1 g/kg of intravenous immunoglobulin every 4 weeks or more experienced disease relapse compared with 50% of those treated with lower or less frequent dosing.

The chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology provided insight on projects they feel are needed to advance the care of patients with migraine-related disorders. [WATCH TIME: 4 minutes]

The chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology discussed some of the key research needs for migraine care going forward. [WATCH TIME: 3 minutes]

An expert neurologist, advocacy director, and a pair of patients with NMOSD discuss the current landscape of the demyelinating disorder.

Annualized attack rate was reduced to 0.08 attacks per year after the first administration of inebilizumab, similar to those who were not previously exposed to rituximab.

An indirect comparison study evaluated relative treatment effects of eculizumab (Soliris; Alexion), inebilizumab (Uplizna; Horizon), and satralizumab (Enspryng; Genentech), the 3 FDA-approved options for NMOSD.